Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -66.37% | 5.51% | -100.00% | -- | -36.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.37% | 5.51% | -100.00% | -- | -36.27% |
| Cost of Revenue | 1,206.13% | 2,606.67% | -33.62% | -92.23% | -91.99% |
| Gross Profit | -3,736.73% | -156,075.00% | 21.95% | 91.42% | 103.34% |
| SG&A Expenses | 95.55% | 72.13% | 86.61% | 17.91% | -9.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.42% | 228.90% | 21.53% | -43.58% | -55.68% |
| Operating Income | -254.87% | -242.96% | -32.46% | 40.54% | 57.64% |
| Income Before Tax | -330.78% | 541.05% | 1,302.91% | -1,119.29% | 16.60% |
| Income Tax Expenses | 1,366.67% | -275.00% | 0.00% | -12.50% | -212.50% |
| Earnings from Continuing Operations | -332.65% | 540.65% | 1,301.79% | -1,118.38% | 16.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -332.65% | 540.65% | 1,301.79% | -1,118.38% | 16.75% |
| EBIT | -254.87% | -242.96% | -32.46% | 40.54% | 57.64% |
| EBITDA | -257.15% | -245.83% | -32.76% | 40.70% | 57.96% |
| EPS Basic | 66.03% | 103.67% | 100.66% | 84.48% | 95.95% |
| Normalized Basic EPS | 34.90% | 115.49% | 103.00% | 46.43% | 97.88% |
| EPS Diluted | 83.01% | 89.44% | 97.26% | 84.48% | 91.91% |
| Normalized Diluted EPS | 34.90% | 107.97% | 103.00% | 46.43% | 97.88% |
| Average Basic Shares Outstanding | 1,167.19% | 2,745.72% | 40,085.40% | 1,661.07% | 1,954.45% |
| Average Diluted Shares Outstanding | 1,167.19% | 5,433.09% | 40,085.40% | 1,661.07% | 1,954.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |